The Macerich Company carries a market capitalization of 6.32B, placing it among publicly traded companies globally. Its enterprise value stands at 9.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.32B |
| Enterprise Value | 9.72B |
The Macerich Company currently has 260.63M shares outstanding.
| Shares Outstanding | 260.63M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
The price-to-sales ratio is 4.80, and the price-to-book ratio stands at -1.25.
| PE Ratio | N/A |
| PS Ratio | 4.80 |
| PB Ratio | -1.25 |
| P/TBV Ratio | 2.05 |
| P/FCF Ratio | 16.04 |
| P/OCF Ratio | 15.55 |
On an enterprise value basis, The Macerich Company trades at an EV/EBITDA multiple of 18.48 and an EV/FCF ratio of 21.74. The EV/Sales ratio of 9.66 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 58.24 provides insight into valuation relative to core operating earnings.
| EV / Sales | 9.66 |
| EV / EBITDA | 18.48 |
| EV / EBIT | 58.24 |
| EV / FCF | 21.74 |
The Macerich Company maintains a current ratio of 0.59, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 198.97, indicating elevated leverage, while an interest coverage ratio of 3.77 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 0.59 |
| Quick Ratio | 0.46 |
| Debt / Equity | 198.97 |
| Debt / EBITDA | 9.51 |
| Interest Coverage | 3.77 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -2.17 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
| Income Tax | -4.01M |
| Effective Tax Rate | N/A |
The Macerich Company's stock has gained approximately 41.22863% over the past 52 weeks. The 50-day moving average sits at 21.21, while the 200-day moving average is 18.92.
| Beta (5Y) | N/A |
| 52-Week Price Change | 41.22863% |
| 50-Day Moving Average | 21.21 |
| 200-Day Moving Average | 18.92 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, The Macerich Company generated 1.01B in revenue and converted that into -183.37M in net income, yielding earnings per share of -0.71. EBITDA reached 525.77M, while operating income came in at 166.87M.
| Revenue | 1.01B |
| Gross Profit | 546.42M |
| Operating Income | 166.87M |
| Pretax Income | -190.81M |
| Net Income | -183.37M |
| EBITDA | 525.77M |
| EBIT | 166.87M |
| Earnings Per Share (EPS) | -0.71 |
The Macerich Company holds 182.03M in cash and equivalents against 5.00B in total debt, resulting in a net debt position of 4.75B. Total book value stands at -3.86B, with working capital of -281.96M providing operational flexibility.
| Cash & Cash Equivalents | 182.03M |
| Total Debt | 5.00B |
| Net Debt | 4.75B |
| Equity (Book Value) | -3.86B |
| Book Value Per Share | -15.09 |
| Working Capital | -281.96M |
The Macerich Company produced 310.49M in operating cash flow over the past twelve months.
| Operating Cash Flow | 310.49M |
| Capital Expenditures | N/A |
| Free Cash Flow | 310.49M |
| FCF Per Share | 1.22 |
The Macerich Company operates with a gross margin of 54.30, reflecting its pricing power and cost economics. The operating margin of 16.58 and net profit margin of -18.22 provide insight into operational efficiency.
| Gross Margin | 54.30 |
| Operating Margin | 16.58 |
| Pretax Margin | -18.96 |
| Profit Margin | -18.22 |
| EBITDA Margin | 52.25 |
The company's payout ratio of -98.21 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.73 |
| Dividend Yield | N/A |
| Payout Ratio | -98.21 |
| Shareholder Yield | 1.81 |
| FCF Yield | 6.23 |
The Macerich Company's most recent stock split took place on February 11, 2010 with a 500:507 split ratio.
| Last Split Date | 2/11/2010 |
| Split Ratio | 500:507 |
The Macerich Company posts an Altman Z-Score of -0.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.01 |